A Randomized Controlled Trial to Assess the  Impact of Clinical Pharmacy Interventions on Treatment Outcomes, Health Related Quality of Life and Medication Adherence Among Hepatitis C Patients

References

• Hanafiah KM, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age‐specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333–1342. doi:10.1002/hep.2614123172780
   PubMed Web of Science ®Google Scholar
• Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29:74–81. doi:10.1111/liv.2009.29.issue-s1
   PubMed Web of Science ®Google Scholar
• Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Inf. 2011;17(2):107–115. doi:10.1111/j.1469-0691.2010.03432.x
   PubMed Web of Science ®Google Scholar
• Organization WH. Guidelines for the Screening, Care and Treatment of Persons with Hepatitis C Infection. World Health Organization; 2014.
   Google Scholar
• Pockros PJ, Reddy KR, Mantry PS, et al. Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology. 2016;150(7):1590–1598. doi:10.1053/j.gastro.2016.02.07826976799
   PubMed Web of Science ®Google Scholar
• Wedemeyer H, Duberg A-S, Buti M, et al. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat. 2014;21:60–89. doi:10.1111/jvh.1224924713006
   PubMed Web of Science ®Google Scholar
• Walker DR, Pedrosa MC, Manthena SR, Patel N, Marx SE. Early view of the effectiveness of new direct-acting antiviral (DAA) regimens in patients with hepatitis C virus (HCV). Adv Ther. 2015;32(11):1117–1127. doi:10.1007/s12325-015-0258-526538232
   PubMed Web of Science ®Google Scholar
• Marcellin P, Chousterman M, Fontanges T, et al. Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real‐life, observational study. Liver Int. 2011;31(4):516–524. doi:10.1111/liv.2011.31.issue-421382162
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Henry L, et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C). J Hepatol. 2014;60(4):741–747. doi:10.1016/j.jhep.2013.12.00624333184
   PubMed Web of Science ®Google Scholar
• Rodis JL, Kibbe P. Evaluation of medication adherence and quality of life in patients with hepatitis C virus receiving combination therapy. Gastroenterol Nurs. 2010;33(5):368–373. doi:10.1097/SGA.0b013e3181f443cb20890160
   PubMed Web of Science ®Google Scholar
• Manns MP. Adherence to combination therapy: influence on sustained virologic response and economic impact. Gastroenterol Clin. 2004;33(1):11–24. doi:10.1016/j.gtc.2003.12.003
   Google Scholar
• Craxi A, Pawlotsky J, Wedemeyer H; European Association for the Study of the Liver, et al. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55:245–264.21371579
   PubMed Web of Science ®Google Scholar
• Surjadi M, Torruellas C, Ayala C, Yee HF, Khalili M. Formal patient education improves patient knowledge of hepatitis C in vulnerable populations. Dig Dis Sci. 2011;56(1):213–219. doi:10.1007/s10620-010-1455-320972850
   PubMed Web of Science ®Google Scholar
• Kolor B. Patient education and treatment strategies implemented at a pharmacist‐managed hepatitis C virus clinic. Pharmacother. 2005;25(9):1230–1241. doi:10.1592/phco.2005.25.9.1230
   Web of Science ®Google Scholar
• Nazareth S, Piercey C, Tibbet P, Cheng W. Innovative practice in the management of chronic hepatitis C: introducing the nurse practitioner model. Aust J Adv Nurs. 2008;25(4):107.
   Web of Science ®Google Scholar
• Smith JP. Treatment options for patients with hepatitis C: role of pharmacists in optimizing treatment response and managing adverse events. Pharmacother. 2008;28(9):1151–1161. doi:10.1592/phco.28.9.1151
   Web of Science ®Google Scholar
• Ravi S, Toosi MN, Karimzadeh I, Ahadi-Barzoki M, Khalili H. Adherence to chronic hepatitis C treatment regimen: first report from a referral center in Iran. Hepat Mon. 2013;13:6. doi:10.5812/hepatmon
   Web of Science ®Google Scholar
• Re III V L, Amorosa VK, Localio AR, et al. Adherence to hepatitis C virus therapy and early virologic outcomes. Clin Inf Dis. 2009;48(2):186–193. doi:10.1086/595685
   Web of Science ®Google Scholar
• Galle PR, Forner A, Llovet JM, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi:10.1016/j.jhep.2018.03.01929628281
   PubMed Web of Science ®Google Scholar
• Pawlotsky J-M, Aghemo A, Back D, et al. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63(1):199–236.25911336
   PubMed Web of Science ®Google Scholar
• Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1):S45–S57. doi:10.1016/j.jhep.2014.07.02725086286
   PubMed Web of Science ®Google Scholar
• Chamorro‐de‐Vega E, Rodriguez‐Gonzalez CG, Gimenez‐Manzorro A, et al. Improving pharmacotherapy outcomes in patients with hepatitis C virus infection treated with direct‐acting antivirals: the GRUviC project. Int J Clin Pract. 2017;71(8):e12988. doi:10.1111/ijcp.12988
   Web of Science ®Google Scholar
• Mariño EL, Álvarez-Rubio L, Miró S, et al. Pharmacist intervention in treatment of patients with genotype 1 chronic hepatitis C. J Managed Care Pharm. 2009;15(2):147–150. doi:10.18553/jmcp.2009.15.2.147
   Google Scholar
• Blobel B. Comparing approaches for advanced e-health security infrastructures. Int J Med Inform. 2007;76(5–6):454–459. doi:10.1016/j.ijmedinf.2006.09.01217074532
   PubMed Web of Science ®Google Scholar
• Pande S, Hiller JE, Nkansah N, Bero L. The effect of pharmacist‐provided non‐dispensing services on patient outcomes, health service utilisation and costs in low‐and middle‐income countries. Cochrane Database Syst Rev. 2013;2.
   Web of Science ®Google Scholar
• Foster GR, Irving WL, Cheung MC, et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;64(6):1224–1231. doi:10.1016/j.jhep.2016.01.02926829205
   PubMed Web of Science ®Google Scholar
• Yang S, Britt RB, Hashem MG, Brown JN. Outcomes of pharmacy-led hepatitis C direct-acting antiviral utilization management at a veterans affairs medical center. J Managed Care Specialty Pharm. 2017;23(3):364–369. doi:10.18553/jmcp.2017.23.3.364
   Google Scholar
• Waheed Y, Shafi T, Safi SZ, Qadri I. Hepatitis C virus in Pakistan: a systematic review of prevalence, genotypes and risk factors. World j Gastroenterol. 2009;15(45):5647. doi:10.3748/wjg.15.564719960560
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879–1888. doi:10.1056/NEJMoa140235524720702
   PubMed Web of Science ®Google Scholar
• Chen J, Florian J, Carter W, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology. 2013;144(7):1450–1455. doi:10.1053/j.gastro.2013.02.03923470616
   PubMed Web of Science ®Google Scholar
• Craxì A, Dusheiko G, Flisiak R. EASL clinical practice guidelines: management of hepatitis C. J Hepatol. 2011;55(2):245–264.21371579
   PubMed Web of Science ®Google Scholar
• Chen AP, Setser A, Anadkat MJ, et al. Grading dermatologic adverse events of cancer treatments: the common terminology criteria for adverse events version 4.0. J Am Acad Dermatol. 2012;67(5):1025–1039. doi:10.1016/j.jaad.2012.02.01022502948
   PubMed Web of Science ®Google Scholar
• Kularatna S, Whitty JA, Johnson NW, Jayasinghe R, Scuffham PA. EQ-5D-3L derived population norms for health related quality of life in Sri Lanka. PLoS One. 2014;9(11):e108434. doi:10.1371/journal.pone.010843425365171
   PubMed Web of Science ®Google Scholar
• Grossberg R, Gross R. Use of pharmacy refill data as a measure of antiretroviral adherence. Curr HIV/AIDS Rep. 2007;4(4):187–191. doi:10.1007/s11904-007-0027-418366950
   PubMedGoogle Scholar
• Alam I, Stainbrook T, Cecil B, Kistler K. Enhanced adherence to HCV therapy with higher dose ribavirin formulation: final analyses from the ADHERE registry. Aliment Pharmacol Ther. 2010;32(4):535–542. doi:10.1111/apt.2010.32.issue-420500732
   PubMed Web of Science ®Google Scholar
• Butt M, Ali AM, Bakry MM, Mustafa N. Impact of a pharmacist led diabetes mellitus intervention on HbA1c, medication adherence and quality of life: a randomised controlled study. Saudi Pharm j. 2016;24(1):40–48. doi:10.1016/j.jsps.2015.02.02326903767
   PubMed Web of Science ®Google Scholar
• Kagawa T, Morizane T, Saito H, et al. A randomized, controlled trial of weekly administration of lymphoblastoid interferon in patients with chronic hepatitis C. J Hepatol. 1993;17(1):91–96. doi:10.1016/S0168-8278(05)80527-68445225
   PubMed Web of Science ®Google Scholar
• Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practiceand problems. Stat Med. 2002;21(19):2917–2930. doi:10.1002/(ISSN)1097-025812325108
   PubMed Web of Science ®Google Scholar
• Asselah T, Boyer N, Saadoun D, Martinot‐Peignoux M, Marcellin P. Direct‐acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN‐free treatment and future perspectives. Liver Int. 2016;36:47–57. doi:10.1111/liv.1302726725897
   PubMed Web of Science ®Google Scholar
• Federico CA, Hsu PC, Krajden M, et al. Patient time costs and out‐of‐pocket costs in hepatitis C. Liver Int. 2012;32(5):815–825. doi:10.1111/liv.2012.32.issue-522221745
   PubMed Web of Science ®Google Scholar
• Smith MA, Love BL, Mohammad RA. The Changing Landscape of Adverse Drug Events Associated with Chronic Hepatitis C Virus Therapy. Taylor & Francis; 2015.
   Google Scholar
• Mohammad RA, Bulloch MN, Chan J, et al. Provision of clinical pharmacist services for individuals with chronic hepatitis C viral infection: joint opinion of the GI/liver/nutrition and infectious diseases practice and research networks of the American College of Clinical Pharmacy. Pharmacother. 2014;34(12):1341–1354. doi:10.1002/phar.2014.34.issue-12
   Web of Science ®Google Scholar
• Wenzler E, Dickson W, Vibhakar S, Adeyemi OM, Danziger LH. Hepatitis C management and the infectious diseases pharmacist. Clin Inf Dis. 2015;61(7):1201–1202. doi:10.1093/cid/civ545
   Web of Science ®Google Scholar
• Foster GR. Quality of life considerations for patients with chronic hepatitis C. J Viral Hepat. 2009;16(9):605–611. doi:10.1111/jvh.2009.16.issue-919674284
   PubMed Web of Science ®Google Scholar
• Weiss JJ, Alcorn MC, Rabkin JG, Dieterich DT. The critical role of medication adherence in the success of boceprevir and telaprevir in clinical practice. J Hepatol. 2012;56(2):503–504. doi:10.1016/j.jhep.2011.05.01421718669
   PubMed Web of Science ®Google Scholar
• Kerpel-Fronius S, Rosenkranz B, Allen E, et al. Education and training for medicines development, regulation, and clinical research in emerging countries. Front Pharmacol. 2015;6:80. doi:10.3389/fphar.2015.0008025926798
   PubMed Web of Science ®Google Scholar
• Lemay V, Hamet P, Hizel C, Lemarié É, Tremblay Y. Personalized medicine: interdisciplinary perspective, world tidal wave, and potential growth for the emerging countries In: Mukesh Verma, editor. Progress and Challenges in Precision Medicine. Elsevier; 2017:301–314.
   Google Scholar
• Larrey D, Ripault M-P, Pageaux G-P. Patient adherence issues in the treatment of hepatitis C. Patient Prefer Adherence. 2014;8:763. doi:10.2147/PPA24920888
   PubMed Web of Science ®Google Scholar
• Rabin R, Oemar M, Oppe M. EQ-5D-3L User Guide, Version 4.0. Rotterdam, Netherlands: EuroQoL Group; 2011.
   Google Scholar